|
WO2020113050A1
|
|
Formulations, methods, kit, and dosage forms for improved stability of an active pharmaceutical ingredient
|
|
WO2019014668A1
|
|
Formulations, methods, kit, and dosage forms for improved stability of an active pharmaceutical ingredient
|
|
US2019008868A1
|
|
Formulations, methods, kits, and dosage forms for treating atopic dermatitis and for improved stability of an active pharmaceutical ingredient
|
|
WO2018187294A1
|
|
Pyrimido-pyridazinone compound combinations, methods, kits and formulations thereof
|
|
KR20190053963A
|
|
P2X3 and / or P2X2 / 3 compounds and methods
|
|
TW201726141A
|
|
Uses of pyrimido-pyridazinones to treat cancer
|
|
EP3307727A1
|
|
Heterocyclic inhibitors of erk1 and erk2 and their use in the treatment of cancer
|
|
AU2014365823A1
|
|
P2X3 and/or P2X2/3 compounds and methods
|
|
US2015125474A1
|
|
Protein-polymer-drug conjugates
|
|
US2016222014A1
|
|
Compounds for regulating fak and/or src pathways
|
|
WO2015038426A1
|
|
Self-immolative linkers containing mandelic acid derivatives, drug-ligand conjugates for targeted therapies and uses thereof
|
|
WO2016018380A1
|
|
Steroid-free disease management
|
|
US2016304617A1
|
|
5t4-targeted immunofusion molecule and methods
|
|
KR20150143672A
|
|
Quinazolines and azaquinazolines as dual inhibitors of ras/raf/mek/erk and pi3k/akt/pten/mtor pathways
|
|
US2014051702A1
|
|
Use of aminoindane compounds in treating overactive bladder and interstitial cystitis
|
|
HUE032240T2
|
|
Cyclohexylamines
|
|
US2013085164A1
|
|
Biaryl imidazole derivatives for regulating CYP17
|
|
MX2014002112A
|
|
Pyrimido- pyridazinone compounds and use thereof.
|
|
KR20200125765A
|
|
Aminoindane compounds and use thereof in treating pain
|
